Skip to main content

Table 3 Mean Change in FACT-EGFRI by Patient-Reported Change in Severity and Impact of Skin Symptoms

From: A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

  FACT EGFRI Total Score
Assessment time A lot better A little bit better About the same A little bit worse A lot worse Mean Diff-erencea
Mean N Mean N Mean N Mean N Mean N  
Change in SEVERITY of skin symptoms
 Day 8    −0.50 4 0.86 69 −6.36 33 −17.53 11  
 Day 15 4.50 2 −1.71 12 0.15 45 −6.96 47 −14.56 16  
 Day 22 4.43 14 3.98 18 − 0.18 50 −3.67 36 −1.33 3  
 Day 29 5.76 20 3.00 23 0.21 55 −2.03 21 −2.5 2  
 Day 36 4.01 16 2.49 28 −0.31 48 0.53 22 −8 1  
 Day 43 2.20 17 0.64 19 0.04 54 −4.52 21 −7.25 4  
 Mean 4.17   1.32   0.13   −3.84   −8.53   3.18
Change in IMPACT of skin symptoms on daily life
 Day 8    −1.33 3 0.05 84 −9.17 23 −20.5 6  
 Day 15 4.5 2 −0.4 10 −1.8 66 −8.73 36 −17.13 8  
 Day 22 3.36 14 8.44 9 −0.75 79 −4.91 17 4 2  
 Day 29 7.43 14 2.86 21 0.44 70 −2.57 14 −5 2  
 Day 36 4.22 16 2.19 18 0.42 70 −1.2 11    
 Day 43 1.91 18 1.23 13 −0.7 71 −5.1 10 −7.33 3  
 mean 4.28   2.17   −0.39   −5.28   −9.19   3.37
  1. aUnweighted mean difference calculated as the average of the difference between adjacent levels of patient-reported change categories. For instance, for severity, the difference is calculated as: mean of [4.17–1.32,1.32–0.13, 0.13-(−3.84), −3.84-(−8.53)]